Publication: Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients
Loading...
Identifiers
Date
2019-12-26
Authors
Rivero-Juarez, Antonio
Vallejo, Nicolau
Lopez-Lopez, Pedro
Díaz-Mareque, Ana Isabel
Frias, Mario
Vallejo, Aldara
Caballero-Gómez, Javier
Rodríguez-Velasco, María
Molina, Esther
Aguilera, Antonio
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Metrics
Export
Abstract
The hepatitis E virus (HEV) is the major cause of acute hepatitis of viral origin worldwide. Despite its usual course as an asymptomatic self-limited hepatitis, there are highly susceptible populations, such as those with underlying immunosuppression, which could develop chronic hepatitis. In this situation, implementation of therapy is mandatory in the sense to facilitate viral clearance. Currently, there are no specific drugs approved for HEV infection, but ribavirin (RBV), the drug of choice, is used for off-label treatment. Here, we present two cases of chronic HEV infection in transplant patients, reviewing and discussing the therapeutic approach available in the literature. The use of RBV for the treatment of an HEV infection in organ transplant patients seems to be effective. The recommendation of 12 weeks of therapy is adequate in terms of efficacy. Nevertheless, there are important issues that urgently need to be assessed, such as optimal duration of therapy and drug dosage.
Description
MeSH Terms
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Organisms::Viruses::Hepatitis Viruses::Hepatitis E virus
Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Ribonucleosides::Ribavirin
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Prescriptions::Off-Label Use
Medical Subject Headings::Diseases::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Organ Transplantation
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression
Medical Subject Headings::Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis E
Medical Subject Headings::Organisms::Viruses::Hepatitis Viruses::Hepatitis E virus
Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Ribonucleosides::Ribavirin
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Prescriptions::Off-Label Use
Medical Subject Headings::Diseases::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Organ Transplantation
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression
Medical Subject Headings::Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis E
DeCS Terms
CIE Terms
Keywords
HEV, Treatment, Zoonoses, Ribavirin, Transplant, Virus de la hepatitis E, Terapéutica, Zoonosis, Ribavirina, Trasplantes
Citation
Rivero-Juarez A, Vallejo N, Lopez-Lopez P, Díaz-Mareque AI, Frias M, Vallejo A, et al. Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients. Microorganisms. 2019 Dec 26;8(1):51